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Abstract 
Background: The risk of cardiovascular diseases (CVD) in human immunodeficiency virus (HIV) infected people 
on antiretroviral therapy (ART) from some rural parts of Africa is not well known. We assessed CVD risk factors, the 
estimated 5‑year Data collection on adverse effects of anti‑HIV drugs (DA.) risk score and the 10‑year Framingham risk 
score in persons with HIV infection on ART in a rural area in South Africa.
Methods: A cross‑sectional study in which the data on demographic, lifestyle, and chronic disease were collected 
using the World Health Organization Stepwise approach to surveillance questionnaire. Biochemical parameters were 
tested using standard biochemical methods. CD4 counts were performed using PIMA analyser and viral load was 
tested using the branched deoxyribonucleic acid technique. Student t test and Chi square test were used on continu‑
ous and categorical variables respectively. Bivariate and multivariate logistic regression were used to analyze predic‑
tors of CVD risk factors. Estimates of 5 and 10‑year CVD risk were calculated using online tools. The Cohen’s kappa 
coefficient was used to assess the agreement between CVD risk equations.
Results: The mean age of participants was 44.8 ± 11.8 years; 79.9 % were females. Most of the participants (85 %) 
had an undetectable viral load and a mean CD4 count of 462 ± 235 cell/mm3. The most common CVD risk factors 
were low high density lipoprotein cholesterol (HDL‑C) (43.8 %), hypercholesterolaemia (33.2 %) and a high Apolipo‑
protein (Apo) B/ApoA ratio (45.4 %).Using the Framingham equation, 6.7 % of participants had a moderate to high 
10‑year CVD risk while the DAD risk equation showed that 31.1 % of participants had a moderate to high 5‑year CVD 
risk. Most participants had a low CVD risk by both risk equations. The level of agreement between the two risk equa‑
tions was 73.8 % (k = 0.23; 95 % CI 0.10–0.35; p value 0.001).
Conclusion: CVD risk factors were common among this rural population on ART. The high proportion of participants 
with a moderate to high CVD risk, observed with the DAD risk equation, clearly represents a considerable health bur‑
den that can possibly be reduced by increasing educational programs on CVD prevention for people on ART. There is 
however a need to develop and evaluate a race/ethnicity‑specific CVD risk estimation tool for HIV infected Africans.
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Background
Human immunodeficiency virus (HIV) or antiretro-
viral therapy (ART) through direct or indirect mecha-
nisms may induce diabetes mellitus, dyslipidaemia, 
hypertension, lipodystrophy and endothelial dysfunc-
tion [1]. Furthermore, some studies have shown that tra-
ditional risk factors for cardiovascular diseases (CVD) 
such as low physical activity, increased body mass index 
(BMI), smoking, are frequently present in HIV infected 
people [2, 3].
A limited number of studies have assessed CVD risk 
factors in HIV infected people on ART from low-income 
countries [4–6]. Furthermore, the number of CVD risk 
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factors, type and duration of ART reported in these stud-
ies varied. Most studies on CVD risk factors in persons 
with HIV infection were done in Western countries 
[7–11]. While some of these studies were conducted in 
areas with people of a low-socio-economic class similar 
to developing countries, differences in ethnicity, environ-
mental, genetic factors, [12–14] and populations’ uptake 
of smoking cessation campaign [9], may have influenced 
prevalence rates of CVD risk factors.
Studies on CVD risk factors among HIV infected peo-
ple are however scarce in South Africa [15, 16]. A recent 
attempt to describe the CVD risk in rural people on 
ART from Mpumalanga in South Africa was made [17], 
but the use of ART was self-reported and according to 
the authors, the prevalence of CVD risk factors in that 
rural population on ART may be underestimated since 
there remains considerable stigma associated with HIV. 
In South Africa, the intersection of an epidemiological 
transition [18], a high number of people living with HIV 
[19] and a widespread adult treatment coverage that was 
close to 80  % by mid-2011 [20], presents a high risk of 
CVD among people infected with HIV and needs to be 
investigated. While CVDs are preventable, little is known 
regarding CVD risk factors in HIV infected rural South 
Africans on ART [17]. We determined the prevalence of 
CVD risk factors, the estimated 5-year DAD risk score 
and the 10-year Framingham risk score in persons with 
HIV infection on ART in a rural area in South Africa.
Methods
Study design
A cross-sectional study was conducted in the primary 
health care clinics, Seobi-Dikgale, Sebayeng and Dik-
gale. At least 74 people with HIV infection are treated 
at Seobi-Dikgale clinic, while 373 people and 377 people 
with HIV infection are treated at Sebayeng and Dikgale 
clinics respectively. The three clinics are situated within 
the Dikgale Health and Demographic Surveillance Sys-
tem (HDSS) site. Dikgale HDSS site is situated about 
70 km to the Northeast of Polokwane, the capital city of 
Limpopo Province. The site consists of 15 villages. Dwell-
ings in Dikgale HDSS are a mix of shacks, conventional 
brick houses and traditional mud huts in the Limpopo 
province of South Africa.
Study participants
During one month all patients, at least 15 years old who 
came to collect their ART were asked to participate in the 
study. Those willing to participate, were advised on the 
participation dates and time (7:00am) at their clinic and 
were advised to provide a fasting sample. Participants 
who could not come on the scheduled date were visited 
in their homes on an arranged date and participated. 
Participants were only included after written informed 
consent was obtained through the completion of a con-
sent form approved by the Medical University of South 
Africa (MEDUNSA) Ethics committee. In the case of 
minors, written informed consent was obtained from 
their legal guardians. Pregnant women were excluded.
Ethical considerations
Ethical approval was obtained from the Ethics Commit-
tee of University of Limpopo, Medunsa campus. Permis-
sion to conduct the study in the Dikgale HDSS site clinics 
was obtained from the Department of Health-Provincial 
office and Primary Health Care Capricorn District office.
Data collection
The study was performed from September 2013 to March 
2014. The World Health Organization stepwise approach 
to surveillance (WHO STEPS) questionnaire [21] was 
used to obtain information on dietary intake, physical 
activity, socio-demographic, tobacco use, alcohol con-
sumption and medical history.
Anthropometric and blood pressure measurements
Anthropometric and blood pressure measurements 
were taken following procedures as previously described 
[22]. In brief, weight was measured to the nearest 0.1 kg, 
using Omron BF 400 (Omron Healthcare, Japan). Height 
was measure to the nearest 0.1 cm, using a stadiometer. 
BMI was calculated as weight (kg)/height (m2). A BMI 
was considered as normal (18.50–24.99), overweight 
(25.00–29.99) and obese (≥30.00) [23]. Waist circumfer-
ence and hip circumference were measured to the near-
est 0.1 cm, using a measuring tape. Both parameters were 
used to calculate the waist to hip ratio. The Omron M5-1 
(Omron Healthcare, Kyoto, Japan) was used to measure 
blood pressure. High blood pressure was defined as a 
systolic blood pressure (SBP) above 140 mmHg and/or a 
diastolic blood pressure (DBP) above 90 mmHg [24] and/
or self-reported history of antihypertensive medication. 
Metabolic syndrome was defined as any three of the fol-
lowing five risk factors; abdominal obesity (waist circum-
ference →  88  cm for females and >102  cm for males), 
high TG concentration (≥1.7 mmol/l), low HDL-C con-
centration (≤1.3 for females and ≤1.1 for males), high 
Blood pressure and raised fasting plasma glucose concen-
tration (>7 mmol/l) [25].
Blood collection
Fasting venous blood samples were drawn by registered 
nurses. Whole blood was used to measure CD4 counts 
on the day of collection. Serum from clotted blood and 
plasma from whole blood were separated through cen-
trifugation at 2000 rpm for 15 min. Glucose was analysed 
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soon after centrifugation using plasma from sodium fluo-
ride tubes. The remaining samples were stored at −80 °C 
until analysis.
Biochemical analysis
Triglycerides (TGs), total cholesterol (TC), high den-
sity lipoprotein (HDL) cholesterol and glucose levels 
were determined on ILab 300 Plus Chemistry System 
(Instrumentation Laboratory Company, Milan, Italy). 
Apolipoprotein B (ApoB), Apolipoprotein A1 (ApoA1) 
were measured on the IMMAGE Immunochemistry 
System (Beckman Coulter, USA). CD4 count was meas-
ured using the Pima Analyser (Inverness Medical, Tokyo, 
Japan). Viral load testing, using the branched deoxyribo-
nucleic acid (DNA) technique (Siemens, South Africa) 
was performed by Toga Molecular Biology and Pathol-
ogy medical laboratory that is South African National 
Accreditation System (SANAS) accredited for ISO 17025.
Statistical analysis
Statistical analysis was performed using Statistical Pack-
age for Social Science version 22. Frequency histogram 
and line graph was used to check normality of continu-
ous variable. The independent Student t-test was used 
to compare continuous variables and the Chi square test 
was used to compare categorical variables between males 
and females. Factors significant at p-value less or equal to 
0.25 in bivariate regression were considered as candidates 
for multivariate modelling. Multivariate logistic regres-
sion was used to determine the significant predictors of 
CVD risk factors. The level of significance for statistical 
analysis was set at less than 0.05. Framingham 10-year 
CVD risk estimation was calculated for each participant 
above 20 years, with no diabetes and no history of CVD, 
by entering the following variables: age, gender, TC, 
HDL-C, SBP, smoking status and current treatment for 
high blood pressure, as required by the Framingham risk 
model tool [26]. Participants were regarded as low risk, 
moderate risk, or high risk when the risk score for devel-
oping CVD in 10 years was <10, 10–20 or >20 % respec-
tively [27]. Variables included in the 5-year DAD risk 
estimation tool were age, sex, SBP, TC, HDL-C, diabetes 
mellitus, smoking status, family history of CVD, cur-
rent use of abacavir, indinavir, or lopinavir and duration 
on indinavir and lopinavir [28]. The risk of developing 
coronary heart disease in the next 5-years was regarded 
as low (<1 %), moderate (1–5 %), high (5–10 %), or very 
high (>10 %) [29]. The level of agreement between DAD 
and Framingham risk equations was determined using 
Cohen’s Kappa coefficient with 95 % CI. For comparison 
with Framingham, participants with high and very high 
scores according to the DAD equation were combined 
and considered as high risk group. Kappa coefficients 
was interpreted as poor agreement (<0), slight agreement 
(0.0–0.20), fair agreement (0.21–0.40), moderate agree-
ment (0.41–0.60), substantial agreement (0.61–0.80) and 
perfect agreement (0.81–1.00) [30].
Results
Characteristics of participants
Two hundred and fourteen HIV infected people on 
ART, participated in the study. Of which 171 (79.9  %) 
were females and 43 (20.1 %) were males. The mean age 
of ART participants was 44.8  ±  11.8  years and males 
were significantly older than females (49.9  ±  11.1 vs 
43.5  ±  11.6, p  =  0.001). The percentage of unmarried 
participants was 164 (76.6  %) with more females than 
males (80.1 vs 62.8 %, p < 0.05). About 45.8 % had sec-
ondary level of education. Unemployment was 69.6  %, 
and higher in females (75.4 %) than in males (46.5 %).
The majority of participants were on efavirenz (86  %) 
and nevirapine (12.5  %) based ART. Only three of the 
participants (1.5  %) were on a lopinavir/ritonavir based 
ART regimen. The mean duration of ART in this study 
was 36 months (range 1–121 months). Most of the par-
ticipants (85  %) had an undetectable viral load and a 
mean CD4 count of 462 ± 235 cell/mm3.
Prevalence of behavioural and metabolic CVD risk factors
Tobacco and alcohol use were higher among males than 
females respectively (39.5 vs 16.5 %, p = 0.001) and (41.9 
vs 17.0  %, p  =  0.001), while more females than males 
were physically inactive (29.1 vs 3.3 %, p = 0.002). Hyper-
triglyceridaemia (35.0 vs 12.5  %, p  =  0.001), high TG/
HDL-C ratio (37.5 vs 13.7  %, p =  0.002) and high TC/
HDL ratio (27.5 vs 10.1  %, p =  0.01) was present more 
often in males than in females (Table 1). None of partici-
pants indicated a family history of cardiovascular disease.
Predictors of metabolic CVD risk factors
People more than 50  years of age were more likely to 
be hypertensive (p  <  0.05) and diabetic (p  <  0.05) com-
pared to people less 50  years of age. In addition an age 
of more than 50 years increased the likelihood of having 
metabolic syndrome (p  <  0.05), a high concentration of 
TG (p < 0.05), a high TC/HDL-C ratio (p < 0.05) and a 
low concentration of HDL-C (p < 0.05) compared to an 
age of less than 50 years. Males were 2.94 times (p < 0.05) 
more likely to have a high TC/HDL-C ratio compared to 
females. People with a viral load of more than 50 cop-
ies/ml (>log 1.71) were less likely to be hypertensive but 
were more likely to have a low HDL-C concentration and 
a high ratio of ApoB/ApoA than people with a viral load 
of less than 50 copies/ml. People on ART for less than 
60  months were less likely to have a high TC/HDL-C 
ratio than people on ART for more than 60 months. The 
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likelihood of having a high TC concentration was 2.10 
times (p  <  0.05) and a high TG/HDL-C ratio was 2.98 
times (p < 0.05) more in people with than in people with-
out abdominal obesity. A low intake of fruit and vegetable 
was associated with a high concentration of TG (p < 0.05) 
(Table 2).
Framingham risk scores
None of the 164 participants according to the Framing-
ham estimation had a high risk of developing a CVD 
event in the next 10  years. However, about 6.7  % had a 
moderate risk and majority had a low risk (93.3 %).
DAD risk scores
Of the 164 participants, 68.9 % had a low risk, 27.4 % had 
a moderate risk and 3.7 % had a combined high and very 
high risk for developing a CVD event in next 5-years. 
However, considering all (214) participants, 66.8  % had 
a low risk, 29  % had a moderate risk, 1.9  % had a high 
risk and 2.3 % had a very high risk for developing CVD in 
next 5-years.
Comparison of the Framingham risk scores with 
the DAD risk scores in 164 participants who met the 
Framingham criteria gave a level of agreement of 73.8 % 
(Kappa = 0.23; 95 % CI 0.10–0.35; p value 0.001) (Table 3).
Table 1 Demographics, HIV information and CVD risk factors in ART treated HIV infected participants by gender
Diabetes—glucose >7 mmol/l and/or history of diabetes, hypertension—systolic blood pressure >140 and/or diastolic blood pressure >90 or history of high blood 
pressure, abdominal obesity—waist circumference >88 cm for females and >102 cm for males, obesity—body mass index ≥30 kg/m2,  low HDL ≤1.3 for females and 
1.1 for males, hypercholesterolaemia—TC ≥ 5 mmol/l, hypertriglyceridaemia—TG ≥ 1.7 mmol/l, high TC/HDL-C >5, TG/HDL-C ≥ 1.49, high ApoB/ApoA >0.68
* ART information was available for 200 participants
ART antiretroviral therapy, HIV human immunodeficiency virus, NVP nevirapine, EFV efavirenz, CVD cardiovascular disease, ApoB apolipoprotein B, Apo A 
apolipoprotein A, TC total cholesterol, HDL-C high density lipoprotein cholesterol. MET-min/wk metabolic equivalent of task-minutes/week
All participants N = 214, n (%) Females N = 171, n (%) Males N = 43, n (%) P-value
Demographics
 Age (years) 44.8 ± 11.8 43.5 ± 11.6 49.9 ± 11.1 0.001
 Unmarried 164 (76.6) 137 (80.1) 27 (62.8) 0.03
 Secondary education 98 (45.8) 83 (48.5) 15 (34.9) 0.12
 Unemployed 149 (69.6) 129 (75.4) 20 (46.5) 0.001
HIV information
 CD4 count (cells/mm3) 461.9 ± 235.3 485.5 ± 234.1 364.3 ± 216.6 0.001
 Viral load (copies/ml) ≤50 ≤50 ≤50 0.14
 Mean duration of ART in months (N = 200) 36.1 ± 24.4 37.0 ± 24.3 32.5 ± 24.6 0.31
 NVP (NNRTI)‑based ART* 25 (12.5) 22 (13.8) 3 (7.5)
 EFV (NNRTI)‑based ART 172 (86) 136 (85.0) 36 (90.0)
 Alluvia (PI)‑based ART 3 (1.5) 2 (1.3) 1 (2.5)
CVD risk factors
 Tobacco use 45 (21.1) 28 (16.5) 17 (39.5) 0.001
47 (22.0) 29 (17 %) 18 (41.9 %) 0.001
 Alcohol use
 Physical activity <600 MET‑min/wk)
38 (24.2) 37 (29.1 %) 1 (3.3 %) 0.002
 Fruit and vegetables intake (<5 servings/day) 150 (95.5) 121 (95.3) 29 (96.7) 1.00
 Obesity 27 (12.7) 25 (14.6) 2 (4.8) 0.12
 Abdominal obesity 51 (23.9) 44 (25.9) 7 (16.3) 0.23
 Hypertension 56 (26.2) 40 (23.4) 16 (37.2) 0.08
 Diabetes 10 (4.7) 6 (3.5) 4 (9.3) 0.12
 Low HDL 91 (43.8) 71 (42.3) 20 (50.0) 0.38
 Hypercholesterolaemia 69 (33.2) 58 (34.5) 11 (27.5) 0.46
 Hypertriglyceridaemia 35 (16.8) 21 (12.5) 14 (35.0) 0.001
 TC/HDL (≥5) 28 (13.5) 17 (10.1) 11 (27.5) 0.01
 High TG/HDL‑C (≥1.49) 38 (18.3) 23 (13.7) 15 (37.5) 0.001
 ApoB/ApoA (≥0.68) 93 (45.4) 74 (44.8) 19 (47.5) 0.86
 Metabolic syndrome 20 (9.6) 15 (8.9) 5 (12.5) 0.56
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Discussion
Although our study population was young, using the 
DAD risk equation  31.1  % of participants had a 5-year 
moderate to high CVD risk. Several factors may play a 
role in causing this high risk. In our study, most people 
were physically active (75.8 %). However, the use of a dif-
ferent instrument for data collection may explain vari-
ations observed in physical activity between our study 
and others [5, 31]. Most participants in our study cited 
non availability of fruits and vegetables coupled with 
unaffordability as reasons for low intake. This low intake 
remains a major challenge as it increases the risk of nutri-
tional deficiencies [32, 33] and CVD incidence and mor-
tality [34]. Consistent with our findings, a low intake of 
fruit and vegetable was reported among the general pop-
ulation of Dikgale HDSS [35].
A high rate of unemployment was observed in this 
study, as was reported in the general population in the 
same community [35]. This high unemployment rate 
coupled with stigma related to HIV infection, may pre-
dispose the HIV infected people to high levels of stress. 
Given that chronic stress predicts the occurance of CVD 
[36], interventions aimed at creation of jobs among HIV 
infected people may therefore play an important role in 
indirectly reducing the risk for CVD, by alleviating stress 
associated with unemployment.
Among metabolic risk factors, hypertension was 
observed in nearly a quarter of participants, consistent 
with a study in Senegal [37]. However other studies that 
included younger populations reported lower prevalence 
rates [6, 38–40]. The prevalence of hypertension was sim-
ilar between males and females. Of the 42 HIV infected 
participants with a history of hypertension and were on 
medication, approximately 60 % had their blood pressure 
controlled, while 40 % had a raised blood pressure despite 
being on medication. Factors contributing to the uncon-
trolled blood pressure include poor adherence to treat-
ment, high salt intake and large alcohol consumption (>3 
drinks per day) [41]. Older age was a predictor of hyper-
tension, and people with a low viral load were more likely 
to be hypertensive. Diabetes mellitus (DM) in males and 
females was low as reported among people on ART in 
other African studies [5, 38, 42, 43]. Unlike our study find-
ings, a high prevalence of diabetes mellitus was reported 
among HIV negative and ART naïve HIV positive people 
in Dikgle HDSS [22], probably due to an older age than 
that of our cohort. The overall prevalence of diabetes mel-
litus among South Africans aged 30  years and above is 
estimated at 9 % equaling a 9.3 % prevalence for United 
States of America [44]. South Africa is undergoing epi-
demiological transition and prevalence of diabetes melli-
tus is thus expected to rise in future [45]. The prevalence 
of obesity (10  %) and abdominal obesity (22  %) in our 
study differed from prevalences reported from Africa [6, 
46] and Asia [40, 47]. According to Crum-Ciaflone et al. 
(2008) [48], the variations in obesity and abdominal obe-
sity may partly be explained by differences in ART dura-
tion and the different cut-off values for the BMI and waist 
circumference used in various studies. Females in our 
study were more likely to be obese than males, although 
the difference was not significant due to the small num-
ber of participants [49]. The prevalence of metabolic 
syndrome was low and similar in males and females. 
Reported prevalences of metabolic syndrome vary, possi-
bly resulting from its heterogeneous nature and variations 
in prevalence of its components [39, 50–52].
The prevalence of hypertriglyceridaemia was low, 
maybe due to the NNRTI based regimen used. The use 
Table 3 Comparison between CVD risk estimation using DAD and Framingham equations
N number, DAD data collection on adverse effects of anti-HIV drugs, CVD cardiovascular disease, CI confidence interval
Cardiovascular disease risk FRAMINGHAM (N = 164)
Low risk (<10 %) Moderate risk (10–20 %) High risk (>20 %)
DAD (N = 164)
 Low risk (<10 %) 113 0 0
 Moderate risk (1–5 %) 37 8 0
 High risk and very high risk (>5 %) 3 3 0
Agreement 73.8 %
Kappa (p‑value) 0.23 (0.001)
95 % CI for Kappa 0.10–0.35
DAD risk estimations on all participants
Low risk (<1 %) Moderate risk (1–5 %) High risk (5.1–10 %) Very high risk (>10 %)
All participants (N = 214) 143 (66.8 %) 62 (29 %) 4 (1.9 %) 5 (2.3 %)
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of a stavudine containing regimen in certain other stud-
ies [40, 53, 54] may explain why a prevalence more than 
twice as high was observed in those studies. In our study 
high concentrations of TG, were more common in males 
than in females, but gender could not predict a high TG 
concentration in multivariate analysis. Abdominal obe-
sity and older age were significant predictors of hypertri-
glyceridaemia as previously reported [55]. High TG levels 
in our study were associated with low intake of fruit and 
vegetables as has been reported in other studies [32, 
33]. Although ART increases lipid levels, HDL-C may 
not return to normal levels thus high prevalence of low 
HDL-C has been observed in this and other studies [6, 
38, 39]. Older age and high viral load were independent 
predictors of a low HDL-C concentration. These results 
show the importance of suppressing the viral load to 
minimize the risk for developing low HDL-C concentra-
tion when people on ART become older. Hypercholester-
olaemia was present in a third of the participants which is 
similar to results from other studies [5, 6, 38, 39]. Visceral 
lipohypertrophy increased the likelihood of having a high 
total cholesterol concentration. None of our participants 
was using lipid lowering drugs, possibly accounting for 
the high proportions of dyslipidaemia. Lipid ratios are 
regarded as better predictors of CVD than individual 
lipids [56, 57]. A high ApoB/ApoA ratio was present in 
nearly 50  % of participants a possible reflection of high 
prevalence of low HDL-C. Its association with high viral 
load in our study predicts the benefits of effective sup-
pression of virus load. Nearly 15 % of participants mostly 
males had a high TC/HDL-C ratio. Older age, longer 
ART duration and male gender, were predictors of a high 
TC/HDL-C ratio. These findings have important impli-
cations as these variables may increase the risk of devel-
oping CVD. A high TG/HDL-C ratio present in nearly a 
fifth of the participants mostly males was associated with 
abdominal obesity.
An earlier study conducted among ART naïve HIV 
infected and HIV negative people in Dikgale Health 
and Demographic Surveillance System site reported a 
high prevalence of CVD risk factors which was similar 
between the two groups [22], but a worse CVD risk pro-
file compared to that of people on ART in the present 
study. Except for hypercholesterolaemia, the prevalence 
for most CVD risk factors in the present study is lower 
than that of ART naïve HIV infected and HIV negative 
in that study. A high prevalence of CVD risk factors 
among the general population in this rural area has pre-
viously been reported [58]. The fact that people on ART 
have monthly consultations at clinics and are informed of 
healthy lifestyles needed to manage co-morbidities could 
possibly explain the lower prevalence of CVD risk factors 
compared to ART naïve and HIV negative from same 
locality. Furthermore majority of participants (96  %) in 
the present study were receiving NNRTI based regimen 
associated with lesser CVD risk compared to PI based 
regimen [27].
Our study found a 73.8 % level of agreement between 
the Framingham and DAD risk estimation equations, 
which was similar to an agreement level of 77.4  % 
reported by Nery et  al. (2013) [59]. Despite this level 
of agreement observed in our study, the Framingham 
equation underestimated the risk for CVD in 43 of the 
164 participants, when compared to the DAD equation. 
These results suggest that the use of the Framingham 
equation in people infected with HIV receiving ART 
may lead to the exclusion of some individuals to benefit 
from more aggressive CVD prevention. The low rate of 
CVD risk as measured by the Framingham equation in 
our study may be that our cohort was relatively young 
and predominantly composed of females. Similar to our 
findings, literature suggests that the Framingham equa-
tion underestimates the risk of CVD in South Africans 
[60]. However, contrary to our findings, the Framingham 
equation overestimated the 10-year CVD risk among 
HIV infected Thais [9] and Brazilians [59] when com-
pared to DAD equation.
Our study is one of the first that assessed a wide range 
of CVD risk factors as well as determined the 10-year 
CVD risk for persons with HIV infection on ART in a 
rural population in South Africa. Limitations of our study 
include its cross-sectional design, therefore we cannot 
conclude that the associations between covariates and 
CVD risk factors are causal. Information on tobacco 
use, alcohol use, physical activity and fruit and vegetable 
intake was obtained using the WHO STEP questionnaire. 
This is considered to be a reliable instrument, however 
recall bias may have influenced the results. Non-random 
sampling was used to recruit participants. However, 
recruitment was conducted for a whole month cycle, giv-
ing all patients collecting their medication equal oppor-
tunity to participant. Follow up on participants who 
failed to turn up for the agreed scheduled date helped 
to reduce selection bias. While our sample may not be 
representative of the whole population of HIV infected 
South Africans receiving ART our study provides valu-
able and useful information for comparison with other 
published studies from both developing and developed 
countries. We also acknowledge the small sample size of 
our study.
Conclusion
The CVD risk factors were common among this rural pop-
ulation on ART. While 6.7 % of participants had a moder-
ate risk, none had a high risk of developing a CVD event 
in the next 10 years, according to Framingham risk score 
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equation. However, the high proportion of people with a 
moderate to very high risk of developing CVD in the next 
5 years according to DAD risk score equation clearly rep-
resents a considerable health burden that can possibly be 
rectified by increasing educational programs on CVD pre-
vention for people on ART. Whilst the DAD equation was 
not developed for Africans, its use instead of the currently 
used Framingham risk table in people on ART in South 
Africa, to identify people with a high CVD risk may help to 
reduce the burden of CVD on the health system. There is a 
need however to develop and evaluate a race/ethnicity-spe-
cific CVD risk estimation tool for HIV infected Africans.
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